Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Future Role of Immunotherapy in Cancer

July 18th 2014

PD-L1 Inhibition With MPDL3280A in Bladder Cancer

July 18th 2014

Adjuvant Ipilimumab in High-Risk Melanoma

July 18th 2014

Checkpoint Inhibitor Combination Strategies

July 18th 2014

Future Role of Checkpoint Inhibitors in Melanoma

July 18th 2014

Checkpoint Inhibitors in Metastatic Melanoma

July 18th 2014

Introduction: Immunotherapy Research Milestones

July 18th 2014

Dr. Movva on Molecular Profiling in Sarcoma

July 16th 2014

Sujana Movva, MD, medical oncologist, Fox Chase Cancer Center, discusses a study presented at the 2014 ASCO Annual Meeting where researchers profiled more than 1900 sarcoma specimens to try to identify potential novel treatment modalities for patients with this disease.

Conclusion: Addressing Unmet Needs in Lung Cancer

July 16th 2014

Potential New Biomarkers in Lung Cancer

July 16th 2014

Novel Angiogenesis Inhibitors in NSCLC

July 16th 2014

Emerging Therapies in Non-Small Cell Lung Cancer

July 16th 2014

PointBreak and AVAPERL Studies in NSCLC

July 16th 2014

Maintenance Therapy Clinical Trials for NSCLC

July 16th 2014

Role of Maintenance Therapy in NSCLC

July 16th 2014

PD-1/PD-L1 Inhibitors Across NSCLC Treatment Settings

July 16th 2014

Multiple PD-1/PD-L1 Agents in Lung Cancer

July 16th 2014

Nivolumab in Non-Small Cell Lung Cancer

July 16th 2014

PD-1 Inhibition in Lung Cancer

July 16th 2014

Efficacy of Next-Generation ALK Inhibitors

July 16th 2014